Cargando…

Initiation and maintenance of a Treat-and-Extend regimen for ranibizumab therapy in wet age-related macular degeneration: recommendations from the UK Retinal Outcomes Group

The treatment of neovascular (wet) age-related macular degeneration (AMD) with ranibizumab is now very well established in terms of efficacy and safety. Recent clinical trials and real-world studies have demonstrated the advantages of a Treat-and-Extend (T&E) regimen, and many hospital departmen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Amoaku, Winfried, Balaskas, Konstantinos, Cudrnak, Tomas, Downey, Louise, Groppe, Markus, Mahmood, Sajjad, Mehta, Hemal, Mohamed, Quresh, Mushtaq, Bushra, Severn, Philip, Vardarinos, Athanasios, Yang, Yit, Younis, Saad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Expert Opinion
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6136415/ https://www.ncbi.nlm.nih.gov/pubmed/30237693 http://dx.doi.org/10.2147/OPTH.S174560

Ejemplares similares

Importance of Anatomical Efficacy for Disease Control in Neovascular AMD: An Expert Opinion
por: Balaskas, Konstantinos, et al.
Publicado: (2021)

Providing a Safe and Effective Intravitreal Treatment Service: Strategies for Service Delivery
por: Amoaku, Winfried, et al.
Publicado: (2020)

24-month clinical outcomes of a treat-and-extend regimen with ranibizumab for wet age-related macular degeneration in a real life setting
por: Vardarinos, Athanasios, et al.
Publicado: (2017)

Resource Use and Real-World Outcomes for Ranibizumab Treat and Extend for Neovascular Age-Related Macular Degeneration in the UK: Interim Results from TERRA
por: Yang, Yit, et al.
Publicado: (2017)

Improving treatment provision of Wet AMD with intravitreal ranibizumab
por: Ghazala, Fadi, et al.
Publicado: (2013)

Macular morphology and response to ranibizumab treatment in patients with wet age-related macular degeneration
por: Dervenis, Nikolaos, et al.
Publicado: (2016)

Intravitreal Ranibizumab in the Treatment of Butterfly-Shaped Pattern Dystrophy Associated with Choroidal Neovascularization: A Case Report
por: Empeslidis, Theodoros, et al.
Publicado: (2012)

Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study
por: Prünte, Christian, et al.
Publicado: (2016)

Individualized Therapy with Ranibizumab in Wet Age-Related Macular Degeneration
por: García-Layana, Alfredo, et al.
Publicado: (2015)

The changing landscape for the management of patients with neovascular AMD: brolucizumab in clinical practice
por: Pearce, Ian, et al.
Publicado: (2022)

Profile of ranibizumab: efficacy and safety for the treatment of wet age-related macular degeneration
por: Chen, Youxin, et al.
Publicado: (2012)

Efficacy of ranibizumab combined with photodynamic therapy on wet age-related macular degeneration
por: Chen, Ling, et al.
Publicado: (2020)

Macular Hole Formation After Intravitreal Ranibizumab Injection in Wet Age-Related Macular Degeneration
por: Mukherjee, Chandoshi, et al.
Publicado: (2015)

Macular morphology and response to ranibizumab treatment in patients with wet age-related macular degeneration [Corrigendum]
Publicado: (2016)

Treatment Satisfaction and Well-Being in Patients with Myopic Choroidal Neovascularization Treated with Ranibizumab in the REPAIR Study
por: Amoaku, Winfried M., et al.
Publicado: (2015)

Subretinal Neovascular Membrane in Wet Age-Related Macular Degeneration Managed With Intravitreal Ranibizumab
por: Sharma, Tanishq S, et al.
Publicado: (2021)

Trastuzumab for HER2-Positive Metastatic Breast Cancer: Clinical and Economic Considerations
por: Jeyakumar, Alwin, et al.
Publicado: (2012)

Aflibercept treatment for neovascular AMD beyond the first year: consensus recommendations by a UK expert roundtable panel, 2017 update
por: Patel, Praveen J, et al.
Publicado: (2017)

Assessment of sleep disordered breathing in patients with heart failure
por: Matthes, Sandhya, et al.
Publicado: (2022)

Ranibizumab for the treatment of wet AMD: a summary of real-world studies
por: Chong, V
Publicado: (2016)

Aflibercept in refractory wet AMD treated with ranibizumab: Anatomical and visual outcome
por: Abou-Ltaif, Sleiman
Publicado: (2016)

Psychological impact of anti-VEGF treatments for wet macular degeneration—a review
por: Senra, Hugo, et al.
Publicado: (2016)

Prognostic Factors of Early Morphological Response to Treatment with Ranibizumab in Patients with Wet Age-Related Macular Degeneration
por: Chrapek, Oldřich, et al.
Publicado: (2015)

Evaluation of Aflibercept Treatment Responses in Eyes with Bevacizumab/Ranibizumab-resistant Wet Age-related Macular Degeneration
por: Topal, Tuncay, et al.
Publicado: (2017)

Intravitreal Aflibercept Versus Ranibizumab for Wet Age-Related Macular Degeneration: A Cost-Effectiveness Analysis
por: Hernandez, Luis, et al.
Publicado: (2018)

Restructuring Wet Age-Related Macular Degeneration Services During the COVID-19 Pandemic to Allow Social Distancing Outpatient Clinics (SDOC)
por: Groppe, Markus, et al.
Publicado: (2021)

Two Year Study of Aflibercept and Ranibizumab Intravitreal Therapy in Patients with Wet AMD
por: Luksa, Dorota, et al.
Publicado: (2021)

New treatment options for fibromyalgia: critical appraisal of duloxetine
por: Üçeyler, Nurcan, et al.
Publicado: (2008)

Al-Hijamah (Prophetic Wet Cupping Therapy) is a Novel Adjuvant Treatment for Viral Hepatitis That Excretes Viral Particles and Excess Ferritin Percutaneously, Synergizes Pharmacotherapy, Enhances Antiviral Immunity and Helps Better HCC Prevention and Treatment: A Novel Evidence-Based Combination with Prophetic Medicine Remedies
por: El Sayed, Salah Mohamed
Publicado: (2023)

Long-Term Visual Outcome in Wet Age-Related Macular Degeneration Patients Depending on the Number of Ranibizumab Injections
por: Calvo, Pilar, et al.
Publicado: (2015)

First-Year Outcomes of Cataract Surgery Combined with Intravitreal Ranibizumab Injection in Wet Age-Related Macular Degeneration
por: Sül, Sabahattin, et al.
Publicado: (2019)

Long-term outcomes of combination photodynamic therapy with ranibizumab or bevacizumab for treatment of wet age-related macular degeneration
por: Rishi, Ekta, et al.
Publicado: (2016)

Ranibizumab and conbercept for treating wet age-related macular degeneration in China: A systematic review and meta-analysis
por: Pengfei, Jiang, et al.
Publicado: (2021)

Randomised, Double-blind, Comparative Clinical Study of New Ranibizumab Biosimilar in Neovascular (Wet) Age-Related Macular Degeneration
por: Apsangikar, Prasad, et al.
Publicado: (2021)

Unusual diagnosis in a patient presenting with fever and bilateral lung infiltrates
por: Petta, Vasiliki, et al.
Publicado: (2021)

Should a clinical rotation in hematology be mandatory for undergraduate medical students?
por: Mandan, Jay, et al.
Publicado: (2016)

Real-World Visual And Clinical Outcomes For Patients With Neovascular Age-Related Macular Degeneration Treated With Intravitreal Ranibizumab: An 8-Year Observational Cohort (AMD8)
por: Horner, Faye, et al.
Publicado: (2019)

Bilateral visual outcomes and service utilization of patients treated for 3 years with ranibizumab for neovascular age-related macular degeneration
por: Chavan, Randhir, et al.
Publicado: (2014)

Use of ziv-aflibercept in diabetic macular edema in a Ghanaian population
por: Braimah, Imoro Zeba, et al.
Publicado: (2022)

Effects of Intravitreal Ranibizumab Injection on Chinese Patients with Wet Age-Related Macular Degeneration: 5-Year Follow-Up Results
por: Lu, Yingyi, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ad13n81r952ulhkb8dn3qcgic8